Advanced EGFR Positive Solid Tumor
Conditions
Keywords
treatment-emergent adverse event (TEAE), dose limiting toxicity (DLT), pharmacokinetic (PK), antidrug antibodies (ADA)
Brief summary
This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to have current standard anti-tumor therapies. The purpose of this study is to determine the maximum tolerated dose (MTD) , to characterise the safety, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of ZZ06 as a single agent in adult participants with advanced solid tumors.
Detailed description
The study will start with an accelerated-titration dose escalation scheme, enrolling 1 patient per cohort for the first 2 cohorts with expansion to 3 patients in the event of Grade ≥ 2 treatment-emergent adverse event (TEAE) or dose limiting toxicity (DLT) possibly, probably, or definitely related to the study drug. After the first 2 cohorts, the study will then proceed to a 3+3 design, with enrollment of 3 patients per cohort and expansion to 6 patients in the event of a DLT.
Interventions
BIOLOGICALZZ06
The phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg.
Sponsors
Covance
Changchun Intellicrown Pharmaceutical Co. LTD
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with histologically or cytologically confirmed advanced solid tumor that is positive for EGFR and has progressed despite standard therapy or for whom no standard therapy exists. * Patients are required to have archival tumor tissue available for assessment of EGFR status via FDA-approved EGFR assay . * Age ≥ 18 years. * Patients must have at least 1 measurable lesion as defined by RECIST v1.1. * Eastern Cooperative Oncology Group performance status of 0 or 1. * Life expectancy ≥ 12 weeks. * Baseline organ function and laboratory data meet the following criteria: 1. Bone marrow： ANC ≥ 1500 cells/mm3； Platelet count ≥ 75 000 cells/mm3； Hemoglobin ≥ 8.0 g/dL. 2. Coagulation： Prothrombin time ≤ 1.5× ULN； Activated partial thromboplastin time ≤ 1.5× ULN； 3. Renal function： Serum creatinine ≤ 1.5× ULN ； estimated glomerular filtration rate≥ 60 mL/min (Cockcroft-Gault formula). 4. Hepatic function： Serum total bilirubin ≤ 1.5 mg/dL； AST and ALT ≤ 3.0× ULN (if metastases are present, ≤ 5.0× ULN). * Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception.Patients must provide written informed consent prior to any study procedures.
Exclusion criteria
* History of another primary cancer ≤ 3 years, with the exception of completely resected nonmelanoma skin cancer or carcinoma in situ of uterine cervix. * Active or symptomatic CNS metastases. Patients with treated CNS metastases that have been stable for ≥ 4 weeks and do not require treatment with steroids or anticonvulsants may be enrolled at the discretion of the Investigator. * Tests positive for hepatitis C virus, hepatitis B virus, or human immunodeficiency virus infection. * Active, clinically significant infections. * Clinically significant cardiovascular disease, including any of the following: 1. Congestive heart failure (New York Heart Association Class \> 2). 2. Serious cardiac arrhythmia. 3. Myocardial infarction ≤ 6 months. 4. Unstable angina. * Prior clinically significant allergic reaction to chimerized or murine monoclonal antibody therapy. * Prior treatment ≤ 6 months with cetuximab, panitumomab, gefitinb, erlotinib, or other therapy that specifically and directly targets the EGF pathway. * Anticancer therapy or investigational agents for nonmalignant disease ≤ 4 weeks or 5 half-lives, whichever is shorter, prior to Cycle 1 Day 1, with the exception of tamoxifen for patients with a history of operated breast cancer \> 3 years and no evidence of disease after surgery. * Major surgery ≤ 4 weeks. * Clinically significant psychiatric illness, other comorbidity, or laboratory abnormality that, in the opinion of the Investigator, makes it unsafe for the patient to participate in the study or may interfere with study compliance or study results. * Other unspecified reasons that, in the opinion of the Investigator, make the patient unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ZZ06 AEs | up to 36 weeks | Adverse events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 |
| Incidence of abnormal laboratory test results | up to 36 weeks | The data of the clinical laboratory evaluation is collected and analyzed according to the time point of the test flow chart |
| Incidence of abnormal physical exam findings | up to 36 weeks | The data of the physical examinations is collected and analyzed according to the time point of the test flow chart |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PK parameters: t1/2 | up to 28 weeks | According to the test schedule, the blood volume of each subject's PK was analyzed and PK analysis was performed. |
| PK parameters: Area under curve (AUC) | up to 28 weeks | According to the test schedule, the blood volume of each subject's PK was analyzed and PK analysis was performed. |
| PK parameters: Vz | up to 28 weeks | According to the test schedule, the blood volume of each subject's PK was analyzed and PK analysis was performed. |
| PK parameters: Cmax | up to 28 weeks | According to the test schedule, the blood volume of each subject's PK was analyzed and PK analysis was performed. |
| PK parameters: Clearance rate (CL) | up to 28 weeks | According to the test schedule, the blood volume of each subject's PK was analyzed and PK analysis was performed. |
Countries
China, United States
Contacts
Primary ContactShiqi Bai
Outcome results
None listed